• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study.

作者信息

Wong Adrian, Jimenez-Zepeda Victor H, Rankin Kathryn, Sandhu Irwin, Chu Michael, Delluc Aurélien, Mian Hira, Stakiw Julie, Cipkar Christopher, McCurdy Arleigh, Patrick Benjamin, Albert Sarah, Henia Meriem, Koo Edward, Sapru Hyra, McCudden Christopher, Visram Alissa

机构信息

University of Ottawa, Ottawa, ON, Canada.

Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.

出版信息

Blood Cancer J. 2025 Aug 29;15(1):149. doi: 10.1038/s41408-025-01352-3.

DOI:10.1038/s41408-025-01352-3
PMID:40883276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397400/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7118/12397400/b6ef6a10e68d/41408_2025_1352_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7118/12397400/b6ef6a10e68d/41408_2025_1352_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7118/12397400/b6ef6a10e68d/41408_2025_1352_Fig1_HTML.jpg

相似文献

1
Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study.普通人群中临床检测到的冒烟型多发性骨髓瘤的发病率和患病率：一项回顾性观察队列研究。
Blood Cancer J. 2025 Aug 29;15(1):149. doi: 10.1038/s41408-025-01352-3.
2
Immunoglobulin G4 Smoldering Multiple Myeloma With Immunoglobulin G4-Related Autoimmune Hepatitis: A Rare Case Report.伴有免疫球蛋白G4相关自身免疫性肝炎的免疫球蛋白G4冒烟型多发性骨髓瘤：一例罕见病例报告
Immun Inflamm Dis. 2025 Aug;13(8):e70244. doi: 10.1002/iid3.70244.
3
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.达雷妥尤单抗或高危冒烟型多发性骨髓瘤的主动监测
N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.
4
The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.干预与观察等待对冒烟型多发性骨髓瘤疾病进展和总生存期的影响：一项随机对照试验的系统评价
J Cancer Res Clin Oncol. 2022 Apr;148(4):897-911. doi: 10.1007/s00432-022-03920-7. Epub 2022 Jan 20.
5
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.采用质谱法对高危美国人群进行筛查后的单克隆丙种球蛋白病患病率及临床结局：一项多中心队列研究。
Lancet Haematol. 2022 May;9(5):e340-e349. doi: 10.1016/S2352-3026(22)00069-2. Epub 2022 Mar 25.
6
Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation.硼替佐米与自体外周血干细胞移植成功治疗冒烟型多发性骨髓瘤相关的I型冷球蛋白血症。
J Clin Exp Hematop. 2025 Jun 28;65(2):121-128. doi: 10.3960/jslrt.25001. Epub 2025 May 30.
7
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.评估冒烟型骨髓瘤临床试验中的早期干预：一项系统综述
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae219.
8
Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials.高危冒烟型多发性骨髓瘤治疗中采用强化治疗（有治愈意向的早期干预）与采用最低强度治疗方案（免疫疾病控制）的对比：来自临床试验的证据的系统评价。
Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e27-e40. doi: 10.1016/j.clml.2022.10.009. Epub 2022 Oct 23.
9
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.利用Flatiron Health数据库分析高危和非高危冒烟型多发性骨髓瘤患者的真实世界特征及预后
Blood Cancer J. 2024 Dec 5;14(1):215. doi: 10.1038/s41408-024-01170-z.
10
Monoclonal Gammopathies in Africa.非洲的单克隆丙种球蛋白病
Clin Lymphoma Myeloma Leuk. 2025 May 31. doi: 10.1016/j.clml.2025.05.023.

本文引用的文献

1
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.达雷妥尤单抗或高危冒烟型多发性骨髓瘤的主动监测
N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.
2
Prevalence of smoldering multiple myeloma based on nationwide screening.基于全国性筛查的冒烟型多发性骨髓瘤患病率。
Nat Med. 2023 Feb;29(2):467-472. doi: 10.1038/s41591-022-02183-6. Epub 2023 Feb 6.
3
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).国际骨髓瘤工作组冒烟型多发性骨髓瘤（SMM）的风险分层模型。
Blood Cancer J. 2020 Oct 16;10(10):102. doi: 10.1038/s41408-020-00366-3.
4
Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic.意义未明的单克隆丙种球蛋白病：梅奥诊所的预测性检测、后续诊断和随访实践的适应证。
Mayo Clin Proc. 2020 May;95(5):944-954. doi: 10.1016/j.mayocp.2019.12.033.
5
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).达雷妥尤单抗单药治疗中危或高危冒烟型多发性骨髓瘤患者的随机、开放标签、多中心、2 期研究（CENTAURUS）。
Leukemia. 2020 Jul;34(7):1840-1852. doi: 10.1038/s41375-020-0718-z. Epub 2020 Feb 5.
6
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.随机 Lenalidomide 对照观察冒烟型多发性骨髓瘤。
J Clin Oncol. 2020 Apr 10;38(11):1126-1137. doi: 10.1200/JCO.19.01740. Epub 2019 Oct 25.
7
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.纳入修订后 IMWG 诊断标准的冒烟型多发性骨髓瘤的风险分层。
Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.
8
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
9
Treatment for high-risk smoldering myeloma.高危冒烟型骨髓瘤的治疗
N Engl J Med. 2013 Oct 31;369(18):1762-3. doi: 10.1056/NEJMc1310911.
10
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.来那度胺联合地塞米松治疗高危冒烟型多发性骨髓瘤。
N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439.